Modifying adaptive therapy to enhance competitive suppression

Elsa Hansen; Andrew F. Read

doi:10.3390/cancers12123556

Modifying adaptive therapy to enhance competitive suppression

Elsa Hansen, Andrew F. Read

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Adaptive therapy is a promising new approach to cancer treatment. It is designed to leverage competition between drug-sensitive and drug-resistant cells in order to suppress resistance and maintain tumor control for longer. Prompted by encouraging results from a recent pilot clinical trial, we evaluate the design of this initial test of adaptive therapy and identify three simple modifications that should improve performance. These modifications are designed to increase competition and are easy to implement. Using the mathematical model that supported the recent adaptive therapy trial, we show that the suggested modifications further delay time to tumor progression and also increase the range of patients who can benefit from adaptive therapy.

Original language	English (US)
Article number	3556
Pages (from-to)	1-13
Number of pages	13
Journal	Cancers
Volume	12
Issue number	12
DOIs	https://doi.org/10.3390/cancers12123556
State	Published - Dec 2020

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers12123556

Cite this

@article{2f5c31f801ad4d3d8711774f2516454a,

title = "Modifying adaptive therapy to enhance competitive suppression",

abstract = "Adaptive therapy is a promising new approach to cancer treatment. It is designed to leverage competition between drug-sensitive and drug-resistant cells in order to suppress resistance and maintain tumor control for longer. Prompted by encouraging results from a recent pilot clinical trial, we evaluate the design of this initial test of adaptive therapy and identify three simple modifications that should improve performance. These modifications are designed to increase competition and are easy to implement. Using the mathematical model that supported the recent adaptive therapy trial, we show that the suggested modifications further delay time to tumor progression and also increase the range of patients who can benefit from adaptive therapy.",

author = "Elsa Hansen and Read, {Andrew F.}",

note = "Funding Information: Funding: This research was funded by Eberly Family Trust. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = dec,

doi = "10.3390/cancers12123556",

language = "English (US)",

volume = "12",

pages = "1--13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "12",

}

TY - JOUR

T1 - Modifying adaptive therapy to enhance competitive suppression

AU - Hansen, Elsa

AU - Read, Andrew F.

N1 - Funding Information: Funding: This research was funded by Eberly Family Trust. Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/12

Y1 - 2020/12

N2 - Adaptive therapy is a promising new approach to cancer treatment. It is designed to leverage competition between drug-sensitive and drug-resistant cells in order to suppress resistance and maintain tumor control for longer. Prompted by encouraging results from a recent pilot clinical trial, we evaluate the design of this initial test of adaptive therapy and identify three simple modifications that should improve performance. These modifications are designed to increase competition and are easy to implement. Using the mathematical model that supported the recent adaptive therapy trial, we show that the suggested modifications further delay time to tumor progression and also increase the range of patients who can benefit from adaptive therapy.

AB - Adaptive therapy is a promising new approach to cancer treatment. It is designed to leverage competition between drug-sensitive and drug-resistant cells in order to suppress resistance and maintain tumor control for longer. Prompted by encouraging results from a recent pilot clinical trial, we evaluate the design of this initial test of adaptive therapy and identify three simple modifications that should improve performance. These modifications are designed to increase competition and are easy to implement. Using the mathematical model that supported the recent adaptive therapy trial, we show that the suggested modifications further delay time to tumor progression and also increase the range of patients who can benefit from adaptive therapy.

UR - http://www.scopus.com/inward/record.url?scp=85096880649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096880649&partnerID=8YFLogxK

U2 - 10.3390/cancers12123556

DO - 10.3390/cancers12123556

M3 - Article

C2 - 33260773

AN - SCOPUS:85096880649

SN - 2072-6694

VL - 12

SP - 1

EP - 13

JO - Cancers

JF - Cancers

IS - 12

M1 - 3556

ER -

Modifying adaptive therapy to enhance competitive suppression

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this